Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Ancell
CD274 [B7-H1/PD-L1] (human)-muIg Fusion Protein
Product Details | |
---|---|
Synonyms | B7-H1; Programmed Cell Death 1 Ligand 1; PD-L1; PDCD1 Ligand 1 |
Product Type | Protein |
Properties | |
Source/Host | CHO cells |
Application |
ELISA |
Formulation | 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5% Gentamicin sulfate |
Protein Negative Control | |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
Declaration | Manufactured by Ancell Corporation. |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | +4°C |
Handling Advice | Avoid freeze/thaw cycles. |
Use/Stability | Stable for at least 6 months after receipt when stored at +4°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
CD274 (B7-H1; PD-L1; Programmed Death Ligand) is a member of the B7 family and is expressed on a variety of tissues including lymphoid cells. It plays an important role in regulation of T cell activation and is involved in progression of cancer, arthritis and HIV infection. CD274 binding to its receptor CD279 (PD-1) on activated T cells can decrease proliferation. Conversely, ligation of CD279 on primed T cells can stimulate IL-10 production. High levels of CD274 present in renal cell carcinoma is associated with poor prognosis. Tumor expressed CD274 can increase apoptosis of tumor specific T cells resulting in better tumor cell survival.